Bolt Biotherapeutics, Inc. (BOLT)
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
Address
900 CHESAPEAKE DRIVE
REDWOOD CITY, CA 94063
Founded
2015
Number of Employees
100
Website
http://www.boltbio.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)